Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22557673 | 0.86 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1PKMSMN1; SMN2 | |
| SCHEMBL22585168 | 0.83 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1PKMSMN1; SMN2 | |
| SCHEMBL18318833 | 0.81 | EPHX2 (0.54) | ALDH1A1EPHX2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5453826 | 0.80 | GPR119 (0.51) | ALDH1A1PKM | |
| SCHEMBL385082 | 0.80 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1PKM | |
| SCHEMBL22557093 | 0.76 | EPHX2 (0.52) | ALDH1A1EPHX2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL27957954 | 0.76 | EPHX2 (0.58) | ALDH1A1EPHX2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL2054713 | 0.75 | CRBN (0.51) | ALDH1A1KMT2AMEN1SMN1; SMN2RAB9A | |
| SCHEMBL23330154 | 0.75 | FPR2 (0.47) | ALDH1A1PKM | |
| SCHEMBL22585310 | 0.75 | EPHX2 (0.51) | ALDH1A1EPHX2KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162836-B2 | N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use | Modern Biosciences Limited (GB) | 2024-12-10 | — | — | US | disclosed |
| CN-113766953-B | N-acyl- {4- [ (4-aryl-phenyl) sulfonylmethyl ] piperidine } compounds and their therapeutic uses | 现代生物科学有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20230022917-A1 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | ISTESSO THERAPEUTICS LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| US-20230022917-A1 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | ISTESSO THERAPEUTICS LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| EP-3956030-A1 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | Modern Biosciences Limited (GB) | 2022-02-23 | — | — | EP | disclosed |
| CN-113766953-A | N-acyl- {4- [ (4-aryl-phenyl) sulfonylmethyl ] piperidine } compounds and their therapeutic use | 现代生物科学有限公司 | 2021-12-07 | — | — | CN | disclosed |
| WO-2020212581-A1 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | Modern Biosciences Limited (GB) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020212581-A1 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | Modern Biosciences Limited (GB) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162836-B2 | N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use | MCL1, BCL9, BCL9L | ALDH1A1 748/4885EPHX2 2957/4885KMT2A 581/4885 |
| US-20230022917-A1 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | MCL1, BCL9, BCL9L | ALDH1A1 748/4885EPHX2 2957/4885KMT2A 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.